Cellebrite (CLBT) CRO details initial share and option stake

Rhea-AI Filing Summary

Cellebrite DI Ltd. executive Marcus Jewell has reported his initial equity holdings in the company. As Global Chief Revenue Officer, he directly holds 453,142 Ordinary Shares. This amount includes several blocks of restricted share units (RSUs) granted in 2023, 2025 and 2026, which vest in quarterly installments from May 2026 through February 2030.

He also holds stock options linked to 301,507 Ordinary Shares at an exercise price of $7.96 per share, expiring on November 14, 2033. Of these options, 169,599 are already vested and exercisable, while 18,844 additional options vest on May 15, 2026 and then every three months through November 15, 2027.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jewell Marcus

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global Chief Revenue Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")	453,142(1)(2)(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options	(4)	11/14/2033	Ordinary Shares	301,507	$7.96	D

Explanation of Responses:

1. Includes 222,096 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on November 15, 2023, of which 31,728 vest on each of May 15, 2026 and every three months thereafter through November 15, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

2. Includes 12,540 Ordinary Shares that are represented by RSUs that were granted on February 11, 2025, of which 1,045 vest on each of May 11, 2026 and every three months thereafter through February 11, 2029.

3. Includes 134,272 Ordinary Shares that are represented by RSUs that were granted on February 10, 2026 and vest as follows: 33,568 vest on the first anniversary of the grant date and 8,392 vest every three months thereafter through February 10, 2030.

4. Of these stock options, 169,599 are fully vested and exercisable and 18,844 vest on each of May 15, 2026 and every three months thereafter through November 15, 2027.

	/s/ Marcus Jewell	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Cellebrite (CLBT) Global Chief Revenue Officer Marcus Jewell report owning?

Marcus Jewell reports direct ownership of 453,142 Ordinary Shares of Cellebrite. This total includes multiple RSU grants that vest over time, plus separate stock options tied to additional Ordinary Shares.

How many Cellebrite (CLBT) shares are covered by Marcus Jewell’s stock options?

Marcus Jewell’s stock options are linked to 301,507 Ordinary Shares. These options have an exercise price of $7.96 per share and an expiration date of November 14, 2033, giving long-dated potential equity exposure.

What RSU grants does Marcus Jewell hold in Cellebrite (CLBT)?

He holds RSUs over 222,096 shares from a November 15, 2023 grant, 12,540 shares from a February 11, 2025 grant, and 134,272 shares from a February 10, 2026 grant, all vesting in scheduled installments through 2030.

When do Marcus Jewell’s RSUs in Cellebrite (CLBT) vest?

RSUs from the November 15, 2023 grant vest in quarterly tranches starting May 15, 2026 through November 15, 2027. Additional RSUs from 2025 and 2026 grants vest every three months from May 11, 2026 through February 10, 2030.

How much of Marcus Jewell’s Cellebrite (CLBT) option grant is already vested?

Out of his stock options over 301,507 shares, 169,599 are already fully vested and exercisable. The remaining options vest in 18,844-share quarterly installments beginning May 15, 2026 and continuing through November 15, 2027.